BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol 2021;14:17562848211064080. [PMID: 34987609 DOI: 10.1177/17562848211064080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Le Thi TG, Werkstetter K, Kotilea K, Bontems P, Cabral J, Cilleruelo Pascual ML, Kori M, Barrio J, Homan M, Kalach N, Lima R, Tavares M, Urruzuno P, Misak Z, Urbonas V, Koletzko S, Sykora J, Miele E, Krahl A, Klemenak M, Papadopoulou A, Chiaro A, Ugras MK, de Laffolie J, Matusiewics K, Rea F, Casswall T, Roma E, Banoub H, Cseh A, Rogalidou M, Lopes AI, for the Helicobacter pylori Special Interest Group of ESPGHAN. Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry. Infection 2022. [DOI: 10.1007/s15010-022-01948-y] [Reference Citation Analysis]
2 Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; 10(19): 6349-6359 [DOI: 10.12998/wjcc.v10.i19.6349] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Inokuchi K, Mori H, Matsuzaki J, Hirata K, Harada Y, Saito Y, Suzuki H, Kanai T, Masaoka T. Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen. Helicobacter. [DOI: 10.1111/hel.12900] [Reference Citation Analysis]
4 Hu Y, Xu X, Ouyang Y, He C, Li N, Xie C, Peng C, Zhu Z, Xie Y, Shu X, Lu N, Zhu Y. Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: A prospective, randomized clinical pilot study. Helicobacter. [DOI: 10.1111/hel.12896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ansari S, Yamaoka Y. Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance. Clin Microbiol Rev 2022;:e0025821. [PMID: 35404105 DOI: 10.1128/cmr.00258-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Graham DY, Moss SF. Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why. Am J Gastroenterol 2022;117:524-8. [PMID: 35081545 DOI: 10.14309/ajg.0000000000001659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lai Y, Wei W, Du Y, Gao J, Li Z. Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives. Gut Microbes 2022;14:2120747. [PMID: 36070564 DOI: 10.1080/19490976.2022.2120747] [Reference Citation Analysis]